South Korea Biosimulation Market (2026-2031)
The South Korea Biosimulation Market was valued at $21.5 Million in 2026 and projected to reach to $32.6 Million by 2031, representing a compound annual growth rate of 15.1%. South Korea's biosimulation market is poised for significant expansion as the nation strengthens its position as a global biotech hub.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea Biosimulation Market Trends and Insights
- This 15.1% compound annual growth rate reflects Mexico's increasing adoption of computational modeling technologies in pharmaceutical development and clinical research.
- Mexico is positioning itself as a key player in Latin America's digital health transformation, driven by rising investments in healthcare infrastructure and growing demand for cost-effective drug development solutions. The biosimulation sector in Mexico benefits from the country's expanding pharmaceutical manufacturing base and strengthening regulatory frameworks aligned with international standards.
- Mexico's proximity to North American markets and its skilled workforce in biotechnology create competitive advantages for biosimulation adoption.
- Between 2026 and 2031, Mexico is expected to see accelerated integration of simulation technologies across preclinical and clinical trial phases, supported by government initiatives promoting healthcare innovation and digital transformation in the life sciences sector..
Key Market Statistics
- CAGR (2026-2031) 15.1% CAGR
- Market Size, 2026 ~USD 21.5 Million
- Forecast, 2031 ~USD 32.6 Million
- Country South Korea
South Korea Biosimulation Market Overview
Strong Market Growth :
South Korea's biosimulation market is valued at $21.5 million in 2026 and projected to reach $32.6 million by 2031, representing a robust 15.1% CAGR, driven by increasing pharmaceutical R&D investments and digital transformation initiatives.
Advanced Healthcare Infrastructure :
South Korea's world-class healthcare system and high digital adoption rates create an ideal environment for biosimulation technologies, with strong government support for biotech innovation and computational drug development.
Pharmaceutical Industry Expansion :
The country's thriving pharmaceutical sector, including major companies and emerging biotech firms, is increasingly leveraging biosimulation for drug discovery, clinical trial optimization, and regulatory submissions.
Government & Academic Support :
South Korea's government initiatives promoting precision medicine and digital health, combined with leading research institutions, are accelerating biosimulation adoption across the healthcare ecosystem.
South Korea Biosimulation Market Dynamics
- The 15.1% CAGR through 2031 reflects growing recognition of computational modeling's value in reducing drug development timelines and costs.
- South Korean pharmaceutical companies are increasingly integrating biosimulation into their R&D pipelines to enhance competitiveness in international markets. The market's growth is supported by robust government funding for digital health initiatives, increasing collaboration between academia and industry, and rising demand for personalized medicine solutions.
- With a highly educated workforce and advanced IT infrastructure, South Korea is well-positioned to become a regional leader in biosimulation adoption, attracting both domestic investment and international partnerships in computational drug development..
Related Ecosystem
Healthcare It
- Computed Tomography (CT)
- Machine Learning
- Magnetic Resonance Imaging (MRI)
- Natural Language Processing (NLP)
- Predictive Analytics
- CERNER CORPORATION
- PHILIPS HEALTHCARE
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Siemens healthineers
Key Takeaways
- Mexico's biosimulation market will grow from $21.5M (2026) to $32.6M (2031) at a 15.1% CAGR.
- Mexico is leveraging its pharmaceutical manufacturing base and regulatory alignment to drive biosimulation adoption.
- Mexico's strategic location and skilled biotech workforce position it as a regional hub for computational drug development.
- Mexico's biosimulation sector is expected to accelerate integration across preclinical and clinical trial phases through 2031.
Biosimulation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | INDIA (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 16.7% from 2026 to 2031 |
| Largest Segment | CONSULTING & ADVISORY (Offering) |
| Market Size Base Year (Billions) | ~USD 4.27 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Type, Application, Therapeutic Area, Revenue Model, Deployment Model, End User, Offering |
South Korea Biosimulation Market Report Segmentation
7 segment dimensions are covered across the global market.
By Type
- Adme/Toxicology
- Clinical Trial Simulation Software
- Clinical Trials
- Consulting & Advisory
- Data Analysis & Interpretation
- Demand Forecasting & Inventory Management
- Implementation, Training, And Support
- Integrated Software Suites/Platforms
- Lead Identification & Optimization
- Molecular Modeling & Simulation Software
- Other Biosimulation Software
- Other Manufacturing & Supply Chain Management Applications
- Pbpk Modeling & Simulation Software
- Phase I
- Phase Ii
- Phase Iii
- Phase Iv/Post-Marketing Surveillance
- Pk/Pd
- Pk/Pd Modeling & Simulation Software
- Preclinical Testing
- Production Planning & Optimization
- Quality Control & Process Monitoring
- Risk Management & Contingency Planning
- Standalone Modules
- Target Identification & Validation
- Toxicity Prediction Software
By Application
- Disease Modeling
- Drug Development
- Drug Discovery
- Manufacturing & Supply Chain Management
- Other Applications
By Therapeutic Area
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Disorders
- Oncology
- Other Therapeutic Areas
By Revenue Model
- License-Based Models
- Pay-Per-Use Models
- Service-Based Models
- Subscription-Based Models
By Deployment Model
- Cloud-Based Models
- Hybrid Models
- On-Premise Models
By End User
- Academic & Research Institutions
- Contract Research Organizations
- Other End Users
- Pharmaceutical & Biotechnology Companies
- Regulatory Bodies
By Offering
- Services
- Software
Target Audience
- Pharmaceutical Companies : South Korean and international pharma firms need this data to assess market opportunities, plan R&D investments in biosimulation technologies, and optimize drug development strategies in this growing market.
- Biotech & Software Vendors : Biosimulation software providers and biotech solution companies require South Korea-specific market insights to identify customer segments, develop localized offerings, and plan market expansion strategies.
- Healthcare Investors : Venture capital, private equity, and institutional investors need detailed South Korea market data to evaluate investment opportunities in biosimulation startups and healthcare technology companies.
- Government & Policy Makers : South Korean health ministry officials and policy makers use this market intelligence to guide digital health initiatives, biotech funding programs, and regulatory frameworks supporting biosimulation adoption.
- Academic & Research Institutions : Universities and research centers in South Korea need market data to align research programs with industry needs, secure funding, and establish collaborations with pharmaceutical and biotech organizations.
Key Companies in the South Korea Biosimulation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CERTARA | United States | Public Company | Biosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools), |
| DASSAULT SYSTÈMES | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline, |
| SIMULATIONS PLUS | United States | Public Company | PBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools, |
| PHYSIOMICS PLC | United Kingdom | Public Company | Oncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics, |
| INSTEM PLC | United Kingdom | Private Company | Research study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics, |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.
CERTARA
Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.
DASSAULT SYSTÈMES
Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.
SCHRöDINGER, INC.
Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
SIMULATIONS PLUS
Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.
PHYSIOMICS PLC
Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.
INSTEM PLC
Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for South Korea ($21.5M in 2026) with verified 15.1% CAGR projections through 2031, enabling accurate business planning and investment decisions in this high-growth market.
- Competitive Landscape Intelligence : Understand South Korea's unique biosimulation ecosystem, including local pharmaceutical players, government initiatives, and academic institutions driving market adoption and innovation.
- Regional Market Positioning : Benchmark South Korea's 15.1% CAGR against the global 16.7% CAGR to identify market maturity levels, growth opportunities, and strategic entry points for biosimulation solutions.
- Regulatory & Infrastructure Insights : Access detailed analysis of South Korea's healthcare infrastructure, regulatory environment, and digital health policies that influence biosimulation adoption and market dynamics.
- Strategic Investment Guidance : Make informed decisions on market entry, partnership development, and resource allocation in South Korea's biosimulation sector with comprehensive market forecasts and trend analysis.
Frequently asked questions
What is the current size of Mexico's biosimulation market?
Mexico's biosimulation market was valued at $21.5 million in 2026 and is projected to reach $32.6 million by 2031.
What is the growth rate of biosimulation in Mexico?
Mexico's biosimulation market is growing at a compound annual growth rate (CAGR) of 15.1% from 2026 to 2031.
What factors are driving biosimulation adoption in Mexico?
Mexico's biosimulation growth is driven by expanding pharmaceutical manufacturing, regulatory framework alignment, government healthcare innovation initiatives, and demand for cost-effective drug development solutions.
How does Mexico's biosimulation market compare to Latin America?
Mexico represents a significant portion of Latin America's biosimulation market, with its 15.1% CAGR reflecting strong regional leadership in computational drug development adoption.
What opportunities exist for biosimulation companies in Mexico?
Mexico offers opportunities through its growing pharmaceutical sector, proximity to North American markets, skilled biotech workforce, and increasing integration of simulation technologies in clinical and preclinical research.
RESEARCH METHODOLOGY
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.
A breakdown of the primary respondents is provided below:
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Biosimulation Market : Top-Down and Bottom-Up Approach
Data Triangulation
The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.
Market Definition
Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.
Key Stakeholders
- Clinical/Physician centers
- Biosimulation vendors
- Clinical research organizations
- Pharmaceutical/Biopharmaceutical companies
- Research & development (R&D) companies
- Business research and consulting service providers
- Medical research laboratories
- Academic medical centers/Universities/Hospitals
- Regulatory agencies
- Clinical researchers
- Accountable care organizations
- Investors and venture capitalists
Report Objectives
- To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Company information
- Detailed analysis and profiling of additional market players (up to 5)
Regional Analysis
- Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Get the Full Biosimulation Market Report
Full forecast, segment splits, and company analysis for all Biosimulation Market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report